CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS
3895  Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations
3897  Bridging the Translational Divide in Oncology: In Vivo Testing of Chemo-sensitivity
Stefan Sleijfer and Martijn Lolkema
See related article, p. 3958

3899  "All Our Wisdom is Stored in the Trees" - Degrading BCR-ABL with Berberis Vulgaris
Shannon Elisabeth Elf
See related article, p. 4040

Reviews
3901  Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Christopher S. Garris and Jason J. Luke

3908  Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines

CLINICAL TRIALS: TARGETED THERAPY

3918  Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

3928  Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Amanda N. Fader, Dana M. Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M. O’Malley, Floor J. Backes, Nicole Nevadunsky, Babak Ehraki, Dirk Pikaart, William Lowery, Karim ElSahwi, Paul Celano, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santini

3936  MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

3947  Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udal Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandrarlapaty, Jose Baselga, and David M. Hyman
Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma


See related commentary, p. 3897

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma


CLINICAL TRIALS: IMMUNOTHERAPY

Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials

Donghua Shi, Yaoping Shi, Ahmed O. Kaseb, Xingxing Qi, Yuan Zhang, Jiachang Chi, Qing Lu, Huiping Gao, Hua Jiang, Huamao Wang, Daijing Yuan, Hong Ma, Hongyang Wang, Zonghai Li, and Bo Zhai

First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma


Preclinical Assessment of 89Zr-CX-072 Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Danique Giesen, Linda N. Broer, Marjolijn N. Lub-de Hooge, Irina Popova, Bruce Howong, Margaret Nguyen, Olga Vasiljeva, Elisabeth G.E. de Vries, and Martin Pool

Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer

Xiaoju Max Ma, Johanna C. Bendell, Herbert I. Hurwitz, Christine Ju, John J. Lee, Alex Lovejoy, Christoph Mancao, Alan Nicholas, Richard Price, Nicolas Sommer, Nalin Tikoo, Lijing Yao, Stephanie J. Yang, and John F. Palma

The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures


Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients

Giuseppe Stragliotto, Mattia Russel Pantalone, Asaf Rahbari, Jari Bartek, and Cecilia Söderberg-Naucler

Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance

Zhao Yin, Guiying Huang, Chunming Gu, Yanjun Liu, Juhua Yang, and Jia Fei

See related commentary, p. 3899

Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy

Sheila Weinmann, Michael C. Leo, Melanie Francisco, Charisma L. Jenkins, Todd Barry, Glen Leesman, Steven P. Linke, Pat W. Whitworth, Rakesh Patel, James Pellicane, Fredrik Wärnberg, and Troy Bremer

Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors

### TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4080</td>
<td><strong>Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma</strong>&lt;br&gt;Flor Mendez, Padma Kadiyala, Felipe J. Nunex, Stephen Carney, Fernando M. Nunex, Jessica C. Gauss, Ramya Ravindran, Sheeba Pasar, Marta Edwards, Maria Belen Garcia-Fabiani, Santiago Haase, Pedro R. Lowenstein, and Maria G. Castro</td>
</tr>
<tr>
<td>4093</td>
<td><strong>A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models</strong>&lt;br&gt;Wei Wei, Yuquan Lin, Zihui Song, Wenming Xiao, Liqi Chen, Jiejing Yin, Yan Zhou, Stefan K. Barta, Michael Petrus, Thomas A. Waldmann, and Yibin Yang</td>
</tr>
<tr>
<td>4143</td>
<td><strong>Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer</strong>&lt;br&gt;Paymaneh D. Malhi, Ryon P. Graf, Angel Rodriguez, Naveen Ramesh, Jerry Lee, Ramsay Sutton, Rhett Jiles, Carmen Ruiz Velasco, Emi Sui, Anand Kolatkar, Christopher Logothetis, Nicholas E. Navin, Paul Corn, Ana M. Aparicio, Ryan Dittamore, James Hicks, Peter Kuhn, and Amado J. Zurita</td>
</tr>
<tr>
<td>4154</td>
<td><strong>FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models</strong>&lt;br&gt;Matthew A. Lakins, Alexander Koers, Raffaella Giambalvo, Jose Munoz-Olaya, Robert Hughes, Emma Goodman, Sylvia Marshall, Francisca Wolerton, Sarah Batey, Daniel Gliddon, Mihriban Tuna, and Neil Brewis</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

The cover shows aggregates of immune cells detected in rhabdomyosarcomas, termed tertiary lymphoid structures (TLS). The image depicts fused single chromogenic stains of immune markers clustering in TLS. TIGIT: purple, CD31: red, CD163: white, CSF-1R: yellow, IDO-1: green, CD8: orange, CD4: light blue, CD3: pink. Stem-like T cells reside in these dense antigen-presenting-cell niches within the tumor TLS. TLS are a major player in antitumor immune responses and are organized structures where intratumoral T and B cells are educated to become effector and memory cells capable of recognizing the tumor. For details, see the article by Chen and colleagues on page 4018 of this issue.